News
Biogaran is acting for people over 60 in Guinea through a large-scale screening campaign for hypertension and diabetes.
Posted on
From October 21 to 25, 2025, Biogaran, the second largest pharmaceutical company in the French generic medicines market, supported a large-scale screening campaign for cardio-metabolic diseases in the cities of Boké and Boffa in Guinea.
Organized by Jean Paul II Hospital, this sixth edition of the screening program enabled more than 1,100 people over the age of 60 to be screened. This mobilization illustrates the importance of this type of initiative in strengthening prevention and raising patient awareness of the health issues associated with these diseases.
In Africa, high blood pressure and diabetes are major public health issues. Their prevalence, already exceedingly high on the continent, continues to increase at an alarming rate[1]. These figures highlight the need to increase screening efforts to promote early diagnosis and appropriate treatment.
Fighting two major diseases in Guinea: hypertension and diabetes
Hypertension and diabetes are now two major health challenges in the country. Their prevalence and fast progression highlight the urgency to raise awareness and promote early diagnosis[1]. In Guinea, nearly 4 in 10 adults aged 30 to 79 are estimated to have high blood pressure, yet only 45% of them are diagnosed and only 7% have their blood pressure controlled by treatment[1].
Diabetes is another major health challenge in Guinea, with an estimated prevalence of 4.6% of the population in 2024, equivalent to 244,600 people, a figure that is likely to be underestimated[2].
A solidarity initiative led by committed stakeholders
For the past three years, Jean Paul II Hospital has been running this annual screening campaign to fight these often-silent chronic diseases. This year, the operation was made possible thanks to the joint support of the Guinean government and Biogaran, which provided the necessary medical equipment and handled the campaign’s organization.
A total of 760 patients were screened in Boké and 350 in Boffa. This partnership marks the first step in Biogaran’s long-term commitment to working alongside local healthcare stakeholders in Guinea to support professionals and improve the long-term management of chronic diseases.
Biogaran long-term commitment to universal access to healthcare:
Biogaran has been present through the distribution of its medicines in Guinea for five years and is actively working alongside healthcare professionals to promote access to high-quality medicines and improve preventive care for patients. This screening campaign is part of this ongoing commitment: supporting local stakeholders to improve diagnosis and treatment and achieve a lasting improvement in the health of the population.
Biogaran offers a range of affordable, high-quality medicines covering both cardio-metabolic conditions and more complex diseases such as cancers, epilepsy or anxiety as well as more common diseases such as infections or allergies.
For more information, you can access the catalogue of medicines available in Guinea by clicking here.
POI 1109-10/25
Sources:
[1] WHO, Global report on hypertension, The race against a silent killer, 2023